-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-6
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2724224-47-7.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2724224-47-7 |
| Description | HBV-IN-6 is a potent inhibitor of HBV with an EC50 of 44 nM. (Extracted from patent WO2021213445A1, compound 3) |
Product Information
| Synonyms | 2-(4-(5-((3R,5S)-5-((3-chloro-4-fluorophenyl)carbamoyl)-6-methyl-1,1-dioxido-1,2,6-thiadiazinan-3-yl)thiophen-2-yl)phenyl)acetic acid |
| IUPAC Name | 2-[4-[5-[(3R,5S)-5-[(3-chloro-4-fluorophenyl)carbamoyl]-6-methyl-1,1-dioxo-1,2,6-thiadiazinan-3-yl]thiophen-2-yl]phenyl]acetic acid |
| Molecular Weight | 538.01 |
| Molecular Formula | C23H21ClFN3O5S2 |
| Canonical SMILES | CN1C(CC(NS1(=O)=O)C2=CC=C(S2)C3=CC=C(C=C3)CC(=O)O)C(=O)NC4=CC(=C(C=C4)F)Cl |
| InChI | InChI=1S/C23H21ClFN3O5S2/c1-28-19(23(31)26-15-6-7-17(25)16(24)11-15)12-18(27-35(28,32)33)21-9-8-20(34-21)14-4-2-13(3-5-14)10-22(29)30/h2-9,11,18-19,27H,10,12H2,1H3,(H,26,31)(H,29,30)/t18-,19+/m1/s1 |
| InChIKey | MEHHLDWOSUGAEW-MOPGFXCFSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 883 |
| Exact Mass | 537.0595190 |
| Target | HBV |
| XLogP3-AA | 3.4 |
